Search results
Results from the WOW.Com Content Network
Nizatidine was developed by Eli Lilly, and was first marketed in 1988. [3] It is considered to be equipotent with ranitidine and differs by the substitution of a thiazole ring in place of the furan ring in ranitidine.
With the development of proton pump inhibitors, such as omeprazole, approved for the same indications, cimetidine is available as an over-the-counter formulation to prevent heartburn or acid indigestion, along with the other H2-receptor antagonists. [12] Cimetidine was developed in 1971 and came into commercial use in 1977.
Use appears to be safe in pregnancy and breastfeeding. [6] How it works is unclear but is believed to involve binding to the ulcer and protecting it from further damage. [3] [6] Sucralfate was approved for medical use in the United States in 1981. [3] It is available as a generic medication.
Cimetidine was the prototypical histamine H 2 receptor antagonist from which later drugs were developed. Cimetidine was the culmination of a project at Smith, Kline & French (SK&F; now GlaxoSmithKline) by James W. Black, C. Robin Ganellin, and others to develop a histamine receptor antagonist that would suppress stomach acid secretion.
Famotidine, sold under the brand name Pepcid among others, is a histamine H 2 receptor antagonist medication that decreases stomach acid production. [4] It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger-Ellison syndrome. [4]
In children, the use of gastric acid inhibitors has been associated with an increased risk for development of acute gastroenteritis and community-acquired pneumonia. [47] A cohort analysis including over 11,000 neonates reported an association of H 2 blocker use, and an increased incidence of necrotizing enterocolitis in very-low-birth-weight ...
When these medications are used long term, the lowest effective dose should be taken. [4] They may also be taken only when symptoms occur in those with frequent problems. [5] Proton-pump inhibitors are named using the suffix "-prazole". There is a purported correlation (but no proven causal link) between the use of PPIs and the risk of dementia ...
Therefore, PPIs are often routinely prescribed for cirrhotic patients to treat GERD and prevent variceal bleeding. However, it has been recently shown that long term use of PPIs in patients with cirrhosis increases the risk of SBP and is associated with the development of clinical decompensation and liver-related death during long-term follow ...